A reproducibility study of novel noninvasive multimodal imaging techniques in atherosclerosis in healthy and cardiovascular diseased subjects - VISUALIZE

Academisch Medisch Centrum0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Group A: 20 subjects with cardiovascular disease.
•-Aged 40 years or older
•-Known with either
•a)A history of cardiovascular disease, such as but not limited to transient ischemic attack (TIA), ischemic stroke, unstable angina pectoris, myocardial infarction or peripheral artery disease.
•b)Cardiovascular risk factors, such as but not limited to hypertension, diabetes mellitus, hypercholesterolemia (LDL > 4.0 mmol/l), low HDL-cholesterol (<1.03 mmol/l), smoking, obesity (BMI > 27 kg/m2).;Group B: 20 young healthy volunteers
•-Aged 40-55 years
•-No history of cardiovascular disease
•-No cardiovascular risk factors ;Group C: 20 older healthy volunteers
•-Aged 55-75 years
•-No history of cardiovascular disease
•-No cardiovascular risk factors

•Exclusion criteria for all subjects;1. Known systemic disorders such as hepatic, renal, hematologic, and malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator.
•2. Standard contra-indications to MRI, 18F-FDG PET, and CT based on physicians experience and current practices (e.g. claustrophobia, metal in the body, as a result of e.g. osteosynthetic material, pacemaker implantation or artificial cardiac valves).
•3. Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.;Exclusion criteria for group A: Cardiovascular patients;1. Changes in dose or frequency of doses of lipid-lowering drugs, antihypertensive drugs or antidiabetic drugs.in the last 6 weeks prior to baseline measurements.
•2. Cardiovascular event in the last 3 months prior to baseline measurements.;Exclusion criteria for group B and C: Healthy volunteers;1. A history of cardiovascular disease
•2. A known elevated risk for cardiovascular disease
•3. Use of any cardiovascular medication, including but not limited to lipid-lowering therapy, antihypertensive drugs, antidiabetic drugs, platelet aggregation inhibitors and anticoagulants.

发起方